This is a distressed financing for a micro-cap biotech. The initial $3M provides a cash runway but the terms are onerous: senior secured status, potential for massive dilution (up to ~63.8M shares vs 7.6M outstanding), and the Company can be forced to issue additional notes. Monitor for stockholder meeting on Exchange Cap waiver (due within 120 days) and SEC effectiveness for the second closing. The stock is likely to trade down on the dilution and debt overhang.
Price Chart
Executive Summary
Cerenome, Inc. entered into a Securities Purchase Agreement on September 4, 2026, to issue up to $21.3 million aggregate principal amount of Senior Secured Convertible Notes to institutional investors. The initial closing involves $3.0 million in net proceeds (after $175k in fees), with a second closing of $2.0 million contingent on SEC registration effectiveness. The company also granted a first-priority security interest in substantially all its assets, including intellectual property, to secure the notes. This is a dilutive debt financing for a micro-cap biotech with a $19M market cap, providing near-term cash but adding significant leverage and potential dilution.
Key Financial Metrics
Key Facts
- Company issued up to $21,276,596 aggregate principal amount of Senior Secured Convertible Notes.
- Initial closing of $3,191,489 in Notes at $940 per $1,000 principal (net ~$3.0M after fees).
- Second closing of $2,127,660 in Notes contingent on SEC registration effectiveness.
- Additional Notes of up to $15,957,447 may be issued at Company's or Buyers' option.
- Notes are senior secured by a first-priority lien on all assets of the Company and its subsidiary CNSide Diagnostics, LLC.
- Proceeds cannot be used for debt satisfaction, stock redemption, or litigation settlement.
- Company must reserve 300% of maximum conversion shares, requiring up to ~63.8M shares based on current stock price.
- Company must seek stockholder approval within 120 days to waive the 19.99% Exchange Cap.
- Lead Buyer 3i, LP appointed as collateral agent; fees up to $225,000 for all closings.
- Company's market cap is ~$19M; the total potential note principal ($21.3M) exceeds market cap.
Financial Impact
Up to $21.3M in convertible debt principal, with initial net proceeds of ~$3.0M. Potential dilution of up to ~63.8M shares (assuming full conversion at Alternate Conversion Price), which would massively dilute existing shareholders.
Risk Factors
- Massive dilution from conversion of up to $21.3M in notes (potential ~63.8M shares vs 7.6M outstanding).
- Senior secured debt structure could impair ability to raise additional capital.
- Second closing and additional closings are contingent on SEC registration, creating execution risk.
- Company must obtain stockholder approval to waive 19.99% Exchange Cap; failure could trigger cash redemption obligations.
- Use of proceeds restrictions limit flexibility; proceeds cannot be used for debt paydown or litigation settlement.
Market Snapshot
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-387267 |
| Document: d382364dex101.htm | 0001193125-26-387267 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 25d ago | 8-K | $1.60 | awaiting T+20 | — | $1.66 (+3.75%) |
Sep 30, 2026 27d ago | Press Release | $1.87 | awaiting T+20 | — | $1.66 (−11.23%) |
Sep 22, 2026 5w ago | Press Release | $2.03 $1.68 | ▼ −17.24% | ▼ −16.68% | $1.66 (−18.23%) |
Sep 16, 2026 5w ago | Press Release | $2.04 $1.74 | ▼ −14.71% | ▼ −17.88% | $1.66 (−18.63%) |
Sep 10, 2026 6w ago | 8-K | $2.39 $1.79 | ▲ +25.10% | ▲ +27.23% | $1.66 (+30.54%) |
Aug 14, 2026 10w ago | Press Release | $3.20 $2.12 | ▲ +33.75% | ▲ +31.77% | $1.66 (+48.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers